External Link - Source: STAT News
Disparities persist under the COVID-19 pandemic. Vulnerable communities to the virus have also been underrepresented in clinical trials. These worries are based on historical examples of discrimination in clinical practice and study design. Building trust between the communities of interest and the vaccine developers is key to higher enrollment, but how can this be facilitated on years of previous distrust and at times, exploitation?